Prof. Moishe Liberman Joins the Team as an Advisor to the Board.
Ontario, Canada | October 2025 – NodeAI is proud to welcome Prof. Moishe Liberman as an Advisor to its Board. Prof. Liberman is an internationally recognized thoracic surgeon and educator, renowned for his groundbreaking work in minimally invasive and endoscopic lung cancer surgery. He currently serves as the Director of the Endoscopic Tracheobronchial and Oesophageal Center (C.E.T.O.C.) at the Centre hospitalier de l’Université de Montréal (CHUM), and is the inaugural Medical Director of CHUM’s Multidisciplinary Robotic, Endoscopic, and Minimally Invasive Surgery Program.
"The intersection of technology and clinical care presents an incredible opportunity to redefine how we diagnose and treat patients," said Prof. Moishe Liberman, Advisor at NodeAI. "This, combined with my passion for advancing lung cancer care through commercialization, led me to the opportunity to work with NodeAI."
As an Advisor, Prof. Liberman will provide guidance on both medical and clinical research matters, while leveraging his extensive entrepreneurial experience. He has played a key role in founding and supporting several innovative startups, including Assist IQ, Ditch Labs, and Endovision, all of which focus on advancing medical technologies. His experience in driving commercialization of medical solutions aligns with NodeAI’s mission to develop AI-powered advancements for lung cancer diagnosis and treatment.
“Professor Liberman’s leadership is the perfect blend of clinical expertise and entrepreneurial insight,” said Mackensey Bacon, CEO and Co-founder of NodeAI. “His experience will help to inform our go-to-market strategy and partnerships. We’re fortunate to have him join our team.”
“Professor Liberman has been a mentor and a significant influence on my career,” said Dr. Wael Hanna, CMO and Co-founder of NodeAI. “His deep knowledge of both the clinical and entrepreneurial landscapes will be an incredible asset to our team as we continue to innovate and push the boundaries of AI in lung cancer care.”
